Ectromelia Virus Infections of Mice as a Model to Support the Licensure of Anti-Orthopoxvirus Therapeutics

by R. Mark Buller, Jill Schriewer, George Painter, Akbar M. Siddiqui, Scott Parker
Published 2010-09-01

Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2

by Wendy Holman, Wayne Holman, Stacy McIntosh, Wendy Painter, George Painter, Jim Bush, Oren Cohen
Published 2021-08-01

Efficacy of CMX001 as a Prophylactic and Presymptomatic Antiviral Agent in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans

by Richard W. Moyer, George Painter, Randall Lanier, Amanda D. Rice, Scott Foster, Bernhard Lampert, Mathew M. Adams, Alice Robertson
Published 2011-01-01

Development of CMX001 for the Treatment of Poxvirus Infections

by George Painter, Merrick Almond, Rose O’Mahony, Wendy Painter, Michelle Rose, Scott Foster, Alice Robertson, Bernhard Lampert, Tim Tippin, Lawrence Trost, Randall Lanier
Published 2010-12-01

Efficacy of CMX001 as a Post Exposure Antiviral in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans

by Scott Foster, Randall Lanier, Alice Robertson, Richard W. Moyer, George Painter, Bernhard Lampert, Brandi R. Manning, Stacey A. Gray, Daniele Swetnam, Andrew J. Smith, Mathew M. Adams, Greg Wallace, Scott F. Lindsey, Andrew M. Burrage, Amanda D. Rice
Published 2011-01-01